Our History

Carlo Erba pharmacy and laboratory established

Farmitalia established, acquires farming estate in Nerviano as veterinary outstation

First ever anthracycline (Adriamycin) approved by FDA

Farmitalia-Carlo Erba merge to form Farmitalia/Carlo Erba (FICE)

FICE acquired by Kabi- Pharmacia To form Pharmacia

Pharmacia merge with The Upjohn Company to become Pharmacia&Upjohn (PNU)

PNU acquire SUGEN, becoming leaders of the kinase field

Aromasin approved by FDA

PNU merge with Searle/Monsanto to become Pharmacia

Pharmacia Acquired by Pfzier

Nerviano site spun off by Pfzier, acquired by CFIC and renamed as “Nerviano Medical Sciences, srl”, (NMS)

Encorafenib enabling IP licensed to Novartis.
Kinase platform agreement with Pfizer renegotiated, and a Region of Lombardy research foundation, “Fondazione Regionale per la Ricerca Biomedica (FRRB) takes over financial control of NMS

Entrectinib, Phase I sponsored by NMS, enters FIH clinical testing, in 3 separate, rationally selected indications.

Encorafenib approved by FDA in 2 independent indications.
Major stake in NMS is acquired by a Shanghai-based Chinese Venture Group, Hefei SARI V-Capital Management Co.

Entrectinib approved by FDA in 2 independent indications

NMS M801; P707; P912 and P807, all targeting different BIC/FIC mechanisms, programs start independent, mutinational, FIH clinical trials

Nerviano Medical Sciences S.r.l. expands US presence: subsidiary’s
Nerviano Medical Sciences Inc. story begins.